logo

XBI

State Street SPDR S&P Biotech ETF·ARCA
--
--(--)
--
--(--)

Key Stats

Assets Under Management
8.34BUSD
Fund Flows (1Y)
647.71MUSD
Dividend Yield
0.36%
Discount/Premium to NAV
-0.02%
Shares Outstanding
66.98M
Expense Ratio
0.35%

About State Street SPDR S&P Biotech ETF

Issuer
State Street Global Advisors
Brand
SPDR
Inception Date
Jan 31, 2006
Structure
Open-Ended Fund
Index Tracked
S&P Biotechnology Select Industry Index
Management Style
Passive
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
SSgA Funds Management, Inc.
Distributor
State Street Corp. (Fund Distributor)
XBI provides exposure to US biotech stocks, as defined by GICS, from a universe that invests across the market-cap spectrum. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market-cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap. The index is rebalanced quarterly.

Classification

Asset Class
Equity
Category
Sector
Focus
Health Care
Niche
Biotechnology
Strategy
Equal
Geography
U.S.
Weighting Scheme
Equal
Selection Criteria
Market cap

Analysis

Sector

Healthcare

100.00%

Asset

Holdings

Symbol

Ratio

logo

MRNA

Moderna
1.89%
logo

MIRM

Mirum
1.53%
logo

RVMD

Revolution Medicines
1.51%
logo

FOLD

Amicus Therapeutics
1.46%
logo

PRAX

Praxis
1.43%
logo

ALKS

Alkermes
1.43%

Symbol

Ratio

logo

PCVX

Vaxcyte
1.43%
logo

HALO

Halozyme Therapeutics
1.40%
logo

GILD

Gilead Sciences
1.39%
logo

KRYS

Krystal Biotech
1.38%

Top 10 Weight 14.85%

10 Total Holdings

See all holdings

Related Funds

Seasonals

Volume Profile

Trade Flow Insight

Community Forum

Loading...

Related News

No articles available

You can ask Aime

No Data